Salix Pharmaceuticals, Inc. is a specialist American pharmaceutical company. It develops drugs and medical devices that prevent and treat various gastrointestinal disorders. It is listed in the Russell 2000 index. This company is listed as having the most revenue per employee by Bizjournals.com. Wikipedia.
Salix Pharmaceuticals | Date: 2016-07-18
The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The invention further provides methods for treating these subjects.
Salix Pharmaceuticals | Date: 2016-09-30
The present invention relates to new rifaximin forms comprising solid dispersions of rifaximin, methods of making same and to their use in medicinal preparations and therapeutic methods.
Salix Pharmaceuticals and Alfa Wasserman S.P.A. | Date: 2016-05-16
25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof is provided. Methods of treatment of bowl related disorders using isolated and/or purified 25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof are also provided.
Suttle A.B.,Salix Pharmaceuticals
British Journal of Cancer | Year: 2014
Background:Pazopanib, an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR)/platelet-derived growth factor receptor (PDGFR)/c-Kit, is approved in locally advanced/metastatic renal cell carcinoma (RCC).Methods:Data from trials in advanced solid tumours and advanced/metastatic RCC were used to explore the relationships between plasma pazopanib concentrations and biomarker changes, safety, and efficacy. Initially, the relationships between pharmacokinetic parameters and increased blood pressure were investigated, followed by analysis of steady-state trough concentration (Cτ) and sVEGFR2, safety, progression-free survival (PFS), response rate, and tumour shrinkage. Efficacy/safety end points were compared at Cτ decile boundaries.Results:Strong correlation between increased blood pressure and Cτ was observed (r2=0.91), whereas weak correlation was observed between Cτ and decline from baseline in sVEGFR2 (r2=0.27). Cτ threshold of >20.5 μg ml-1 was associated with improved efficacy (PFS, P<0.004; tumour shrinkage, P<0.001), but there was no appreciable benefit in absolute PFS or tumour shrinkage from Cτ >20.5 μg ml-1. However, the association of Cτ with certain adverse events, particularly hand–foot syndrome, was continuous over the entire Cτ range.Conclusions:The threshold concentration for efficacy overlaps with concentrations at which toxicity occurs, although some toxicities increase over the entire Cτ range. Monitoring Cτ may optimise systemic exposure to improve clinical benefit and decrease the risk of certain adverse events.British Journal of Cancer advance online publication, 28 October 2014; doi:10.1038/bjc.2014.503 www.bjcancer.com. © 2014 Cancer Research UK
Salix Pharmaceuticals | Date: 2016-04-28
The present invention relates to Rifaximin amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
Salix Pharmaceuticals | Date: 2015-01-26
Treatment of travelers diarrhea using in subjects having hepatic encephalopathy using gastrointestinal specific antibiotics is disclosed. One example of a gastrointestinal specific antibiotic is rifaximin.
Salix Pharmaceuticals | Date: 2016-02-01
The invention relates to formulations and dosage schedules of balsalazide. The invention further relates to methods of producing pharmaceutical formulations of balsalazide.
Salix Pharmaceuticals | Date: 2015-08-03
Embodiments relate to Rifaximin polymorphic, salt, and hydrate forms, methods of producing polymorphic forms and to their use in medicinal preparations and to therapeutic methods using them.
Salix Pharmaceuticals | Date: 2015-11-05
The present invention provides new methods and kits for the reduction, prevention or inhibition of substrate uptake by non-metastatic, metabolically active cells in a subject who will undergo a position emission tomography (PET) scan.
Salix Pharmaceuticals | Date: 2016-01-14
The present invention relates to Rifaximin polymorphic forms, to their use in medicinal preparations and to therapeutic methods using them.